Menu
← Oncology Approval Tracker
FDA DECISION ·
Udenyca autoinjector
pegfilgrastim-cbqv · Coherus BioSciences
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
A 6 mg single-dose prefilled autoinjector presentation to reduce infection risk associated with febrile neutropenia in eligible patients with nonmyeloid cancers receiving myelosuppressive therapy.
LAMPGEN ANALYSIS
Why it matters
The FDA approved another way to administer the existing pegfilgrastim biosimilar.
What research teams should watch
Track the delivery presentation in the medication record and verify patient training and timing after chemotherapy.
PRIMARY RECORDS